Ardelyx develops novel oral therapeutics to treat mineral metabolism and metabolic disorders.
Ardelyx develops novel, first-in-class oral therapeutics to correct mineral metabolism and metabolic disorders. The Company's molecules, whose systemic exposure is severely restricted, target transporters and receptors, modulating the uptake of nutrients or inducing secretion of key hormones to produce a therapeutic benefit in patients. The Company's non-systemic products act from within the intestines to avoid potential side effects that could occur with systemic exposure. The Company's lead product, RDX5791, a minimally-absorbed, orally administered NHE3 sodium transport inhibitor, is being developed both for constipation-predominant irritable bowel syndrome (IBS-C) and for prevention of excess dietary sodium absorption, a new treatment modality for high blood pressure. RDX5791 is in phase 2 for IBS-C and a dose-ranging/regimen study for inhibition of excess dietary sodium absorption. Ardelyx is also developing RDX002, a minimally-absorbed, orally administered NaP2b phosphate transport inhibitor for the inhibition of phosphate absorption in patients with chronic kidney disease, and RDX009, a minimally-absorbed, orally administered TGR5 agonist for the treatment of type 2 diabetes through direct induction of intestinal incretins such as GLP-1 and PYY. Both RDX002 and RDX009 are in preclinical development. To date, Ardelyx has raised $56M in venture and angel funding since it was founded in 2007. Ardelyx is located in Fremont, California.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 30, 2022 | Post-IPO Debt | $20M | 2 | HealthCare Royalty Partners | — | Detail |
Feb 24, 2022 | Post-IPO Debt | $27.50M | 1 | SLR Capital Partners | — | Detail |
May 21, 2018 | Post-IPO Debt | $50M | — | — | — | Detail |
Jul 18, 2016 | Post-IPO Equity | $110M | 10 | — | — | Detail |
Jun 22, 2015 | Post-IPO Equity | $77.77M | 7 | New Enterprise Associates | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
HealthCare Royalty Partners | Yes | Post-IPO Debt |
SLR Capital Partners | Yes | Post-IPO Debt |
Amgen Ventures | Yes | Series B |
Kyowa Kirin | — | Post-IPO Debt |
Cormorant Asset Management | — | Post-IPO Equity |
Dafna Capital Management | — | Post-IPO Equity |
Deepfield | — | Post-IPO Equity |
EcoR1 Capital | — | Post-IPO Equity |
First Manhattan Consulting Group | — | Post-IPO Equity |
New Enterprise Associates | — | Post-IPO Equity |